Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources
The Majority of Physicians Surveyed in China and South Korea Say Significant Differences Exist Between Biosimilars and Reference Brands, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed South Korean oncologists are significantly less familiar with biosimilars than oncologists surveyed in Europe. This finding is in spite of the fact that South Korea has had an approval pathway for biosimilars since 2009 and the world's first biosimilar monoclonal antibody, Celltrion's Remsima (infliximab), was launched in South Korea.
The Strategic Insights report entitled Physician Perspectives on Biosimilars in South Korea and China finds that Chinese specialists have a similar level of familiarity with biosimilars to South Korean oncologists, even though no biosimilars exist in China (although locally produced biologics that have not demonstrated comparability to the related multinational brand are available). The report also finds that South Korean and Chinese specialists generally perceive that there are significant differences between biosimilars and their reference brands.
"Over time, we expect physician familiarity with biosimilars to increase, driven by the growing number of biosimilars trials presented at major meetings, the expected introduction of a biosimilars pathway in China and the launch of oncology-specific biosimilars in South Korea," said Decision Resources Group Director of Biosimilars Research Kate Keeping. "Generally, as physicians' familiarity increases, so does the likelihood that they will perceive biosimilars to have no clinically meaningful differences to the reference brand, as the regulatory definitions stipulate."
About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.